The AFORRD trial is asking three important questions: What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given with or without a statin? Are there simple techniques that can help people to take their tablets on a regular basis?
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
810
Prim objective (16 wks) for atorvastatin: Proportion of pats. who achieve measured
LDL levels <2.6 mmol/L (<100 mg/dl) Prim object (16 wks) for Omega-3 fatty acid:
Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl)
Prop of pats who achieve LDL levels <2.6 mmol/L (<100 mg/dl) at 52 weeks, taking into account whether the patient received additional atorvastatin therapy or placebo at week 16.
Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Irvine, Ayrshire, United Kingdom
Pfizer Investigational Site
Farnworth, Bolton, United Kingdom
Pfizer Investigational Site
Thornhill, Cardiff, United Kingdom
Pfizer Investigational Site
Fowey, Cornwall, United Kingdom
Pfizer Investigational Site
Launceston, Cornwall, United Kingdom
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom
Pfizer Investigational Site
Saltash, Cornwall, United Kingdom
Pfizer Investigational Site
St Austell, Cornwall, United Kingdom
Pfizer Investigational Site
Darlington, County Durham, United Kingdom
...and 49 more locations